These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20811704)

  • 21. Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.
    Liu S; Gong J; Morishita A; Nomura T; Miyoshi H; Tani J; Kato K; Yoneyama H; Deguchi A; Mori H; Mimura S; Nomura K; Himoto T; Deguchi K; Okano K; Izuishi K; Suzuki Y; Kushida Y; Haba R; Iwama H; Masaki T
    Exp Ther Med; 2011 May; 2(3):399-403. PubMed ID: 22977516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway.
    Xu J; Zhang S; Wang R; Wu X; Zeng L; Fu Z
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28432271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
    Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
    Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
    Barbacci EG; Pustilnik LR; Rossi AM; Emerson E; Miller PE; Boscoe BP; Cox ED; Iwata KK; Jani JP; Provoncha K; Kath JC; Liu Z; Moyer JD
    Cancer Res; 2003 Aug; 63(15):4450-9. PubMed ID: 12907618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
    Liu W; Zhang J; Yao X; Jiang C; Ni P; Cheng L; Liu J; Ni S; Chen Q; Li Q; Zhou K; Wang G; Zhou F
    Cancer Sci; 2018 Oct; 109(10):3294-3304. PubMed ID: 30151975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
    Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
    Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
    Wang LH; Chan JL; Li W
    Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
    Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
    Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells.
    Kuwada SK; Scaife CL; Kuang J; Li X; Wong RF; Florell SR; Coffey RJ; Gray PD
    Int J Cancer; 2004 Mar; 109(2):291-301. PubMed ID: 14750183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
    Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
    Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
    Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft].
    Zhao J; Zhao T; Xie F; He B
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):890-3. PubMed ID: 22699078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Jiao Y; Ou W; Meng F; Zhou H; Wang A
    Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
    Yokoi K; Thaker PH; Yazici S; Rebhun RR; Nam DH; He J; Kim SJ; Abbruzzese JL; Hamilton SR; Fidler IJ
    Cancer Res; 2005 May; 65(9):3716-25. PubMed ID: 15867367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
    Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
    Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.